Introduction {#S1}
============

The zoonotic transmission and subsequent adaptation to humans of emerging RNA viruses is a global public health concern. In the 21st century alone, coronaviruses (CoV) have been responsible for two separate endemics, the [s]{.ul}evere [a]{.ul}cute [r]{.ul}espiratory [s]{.ul}yndrome (SARS) and [M]{.ul}iddle [E]{.ul}ast [R]{.ul}espiratory [S]{.ul}yndrome (MERS) CoVs ([@B61]). In late Dec 2019, a novel SARS-like CoV designated 2019 nCoV emerged in Wuhan China, causing \> 60,000 cases and over 1350 deaths in an ongoing epidemic ([@B105]). Other highly pathogenic threat viruses that have emerged in the 21st century include influenza viruses, Ebola viruses, flaviviruses and paramyxoviruses ([@B155]). The high mutation and recombination rate of RNA viruses drives the emergence of new viral strains that can rapidly adapt to new and changing ecologies ([@B68]; [@B131]). Furthermore, industrialization, globalization and traditional cultural habits potentiate the likelihood of zoonotic transmission and facilitate the spread of viruses in the human population. While new outbreaks from emergent viruses are inevitable, scientists, epidemiologists, and the health care industry are racing to develop new technologies to better predict and minimize the impact of an outbreak by employing global viral surveillance programs and developing vaccines and antivirals ([@B144]). A major challenge of vaccine and antiviral development is the elusive nature of the emerging viruses, which oftentimes emerge from highly heterogeneous populations of virus strains that circulate in animal reservoirs ([@B131]). Therefore, to prepare for future outbreaks, vaccines and antivirals will need to be both potent and broadly effective against multiple potential emerging viruses within and across virus families. Additionally, in order to control and prevent viral spread, treatments must be readily available to affected populations and have a fast response time. In this review, we will focus our discussion on the challenges, as well as current development, of vaccines and antivirals for SARS-CoV and MERS-CoV. At the end, we will also discuss the potential use of AAV-based gene therapy as a quick response to prevent and treat emerging viral infections in the current SARS-CoV-2 and future outbreak situations.

Endemic and Emerging Coronaviruses {#S1.SS1}
----------------------------------

Coronaviruses are a diverse group of positive-stranded RNA viruses which infect a wide range of animals from birds to mammals, causing a variety of diseases ([@B193]; [@B261]; [@B189]). Based on sequence identity of the spike protein or the non-structural proteins (nsp), CoVs are classified into four different sub-groups, *alphacoronaviruses*, *betacoronaviruses*, *gammacoronaviruses*, and *deltacoronaviruses* ([Figure 1](#F1){ref-type="fig"}). Human coronaviruses (hCoVs), such as 229E, OC43, NL-63 and HKU-1 are highly transmissible respiratory viruses which are responsible for around 10-20% of common cold cases annually ([@B161]; [@B33]). HCoV-related illness is often self-limited in immune competent individuals but may cause more severe upper and lower respiratory tract infections in the young and elderly population ([@B262]; [@B130]). In addition, highly pathogenic CoVs may emerge through zoonotic reservoirs. In the past two decades, SARS-CoV and MERS-CoV emerged from bats and spread to humans through intermediate hosts including civet cats and camels, respectively ([@B203]). SARS-CoV and MERS-CoV belong to the sub-groups 2b and 2c of the *Betacoronavirus* genus ([@B189]). The latest CoV outbreak is the SARS-CoV-2, a *Betacoronavirus* 2b which emerged from bats and spread to humans ([@B151]). The mortality rate of these viruses range from 10 to 40% but can exceed 50% in the elderly ([@B170]; [@B136]; [@B29]; [@B203]; [@B216]; [@B263]). The unusually high mortality rate is linked to disease progression leading to acute respiratory distress syndrome (ARDS) which causes hypoxemia, pulmonary edema, and infiltration of inflammatory immune cells in the lung ([@B33]; [@B89]). If unresolved, the diseases progress to late phase ARDS, leading to end-stage lung disease and death ([@B67]). Currently, no vaccines or antiviral drugs are approved to prevent or treat severe CoV infection.

![Spike and nsp12 phylogeny of representative coronaviruses. The Spike **(A)** and nsp12 **(B)** protein sequences of selected coronaviruses were aligned and phylogenetically compared. Coronavirus genera are grouped by classic subgroup designations (1, 2a-d, 3, and 4). In the Spike tree in **(A)**, SADS-CoV is designated as 1\* because of its distinctive grouping compared with more conserved proteins (e.g., nsp12, see **(B)**). Branches in each tree are labeled with consensus support values (in %). Sequences were aligned using free end gaps with the Blosum62 cost matrix, and the tree was constructed using the neighbor-joining method based on the multiple sequence alignment in Geneious Prime. Numbers following the underscores in each sequence correspond to the GenBank Accession number. The SARS-CoV-2 is highlighted in red. The radial phylogram was exported from Geneious and then rendered for publication using Adobe Illustrator CC 2020.](fmicb-11-00658-g001){#F1}

The Challenge for Vaccine Development {#S1.SS2}
-------------------------------------

The CoV *S*-protein is the major envelope glycoprotein and the main determinant of protective immunity. The *S*-protein is composed of two principle subunits, S1 and S2; S1 governs receptor binding and S2 is responsible for membrane fusion ([@B134]). Similar to other class I fusion proteins, *S*-protein undergoes a major conformational change between pre-fusion and post-fusion which also presents different antigenic epitopes. While able to bind to both conformations, Abs targeting the post-fusion form are not necessary neutralizing; in contrast, Abs targeting the pre-fusion form of the *S*-protein correlate better with neutralization. In particular, vaccines and neutralizing antibodies (nAbs) which target the receptor binding domain (RBD) of the *S*-protein can effectively neutralize the virus ([@B285]; [@B235]). However, due to high selective pressure and tropism determinants, *S*-protein is the most diverse region of CoV. For instance, the *S*-proteins from SARS-CoV and MERS-CoV share only 44% sequence identity ([@B113]). The majority of differences between *S*-proteins is in the S1 region, which is further separated into the N-terminal Domain (NTD) and RBD. The diverse nature of the RBD between SARS-CoV and MERS-CoV is reflected in the use of different entry receptors, either angiotensin I converting enzyme 2 (ACE2) or dipeptidyl peptidase 4 (DPP4), respectively ([@B135]; [@B201]). The diversity of *S*-protein also renders vaccines and nAbs unlikely to be cross-protective between existing and emerging CoVs. Surveillance and experimental data have identified multiple animal SARS- and MERS-like CoVs that have significant diversity in *S*-protein and are able to replicate in human cells without adaptation ([@B164], [@B166]; [@B152]). Once transmitted to human population, such variation between *S*-protein between the previous and the new emerging CoVs will pose a major challenge on the progress of vaccine development.

Criteria for Generating Effective Vaccine for CoVs {#S2}
==================================================

Vaccine Criteria for SARS and MERS-CoV Viruses {#S2.SS1}
----------------------------------------------

The surface glycoproteins are the main target for vaccine development. In CoV infection, Abs against *S*-protein were shown to be protective in multiple animal studies. Furthermore, in a passive immunization study in camel, the nAb level is directly correlated to lung pathology and survival ([@B281]). As such, one of the main goals for CoV vaccines in humans is the ability to elicit a strong humoral immune response against the *S*-protein. Particularly, the pre-fusion form of the *S*-protein is an attractive target for Abs to confer protective immunity. In order to "lock" the *S*-protein in its antigenic optimal pre-fusion form, two mutations, V1060P and L1061P, were introduced into the MERS-CoV *S*-protein ([@B186]). The resulting MERS S-2P is able to elicit both RBD and non-RBD binding nAbs ([@B186]). The same strategy was also shown to work in the SARS-CoV-2 *S*-protein ([@B264]). Other structural proteins such as E and M and the nsp N also contribute to viral protection and clearance ([@B41]; [@B283]; [@B64]). Similarly to other respiratory viruses such as influenza, mucosal IgA plays a major role in disease protection and has a synergistic effect with IgG ([@B23]; [@B196]). In order to elicit a strong mucosal IgA immunity, the route of vaccine administration is important. Studies have shown that intranasal inoculation of a recombinant RBD vaccine can elicit greater mucosal IgA production than intramuscular or subcutaneous injection ([@B153]). However, the duration of mucosal antibodies is typically shorter lived than systemic IgG responses and the longest longitudinal study of MERS-CoV IgA responses ended after 6 months ([@B95]; [@B153]). In comparison, in a natural infection case study, SARS-targeting systemic memory B cells were present up to 6 years for SARS-CoV ([@B182]; [@B233]); and up to 34 months post infection for MERS-CoV ([@B188]). Another important consideration for SARS-CoV and MERS-CoV vaccination is the T cell response against the virus, specifically the N proteins, which is important for viral clearance ([@B282]; [@B41]). A study has shown that adoptive transfer of viral specific T-cells to SCID mice enhances survival and reduces lung titer after SARS-CoV infection ([@B282]). Moreover, intranasal vaccination of N protein using the VEEV replicon system elicits CD4+ memory T-cells responses in the airway. Upon challenge, the airway CD4+ memory T cells secrete IFN-γ, which subsequently enhances the innate immune response as well as coordinates the CD8+ T cell priming and migration which protects mice from lethal disease, but not weight loss or virus titers under carefully controlled conditions ([@B283]). Interestingly, Rag−/− mice are able to clear SARS-CoV infection, suggesting innate immunity is sufficient for viral clearance ([@B282]). However, the mechanism of this viral clearance is still unknown. Another important aspect of emerging CoV vaccine is the breadth of protection. As mentioned previously, the antigenic variation in the *S*-protein between CoVs limits the breadth of cross protection against multiple emerging CoVs, and is especially true for *S*-protein only vaccines ([@B252], [@B255]).

Learning from natural infection, MERS-CoV specific CD4+ and CD8+ T cells are detected in PBMCs in MERS-CoV infected survivors ([@B280]). Therefore, a balance of B cell and T cell responses is generally considered the gold standard to prevent and resolve MERS-CoV and SARS-CoV infection. Multiple strategies have been developed to elicit long lasting B and T cell responses for SARS-CoV and MERS-CoV. These include the traditional live attenuated, inactivated, and subunit vaccines, and newer development of nanoparticles, vectorized vaccines, and RNA/DNA vaccines. In this review, we have selected only the vaccine studies that have an *in vivo* challenge model and have summarized the different parameters, including vaccine components, dosage, challenge conditions, animal models and the study outcome in [Table 1](#T1){ref-type="table"}. We will also discuss each type of vaccine strategy and focus on the finished clinical trial targeting SARS-CoV and the 3 ongoing clinical trials targeting MERS-CoV using DNA ([@B158]; [@B172]) and vectorized vaccines. Other comprehensive reviews on CoV vaccine development can be found elsewhere ([@B278]; [@B70]; [@B194]; [@B211]; [@B271]).

###### 

Summary of SARS-CoV and MERS-CoV vaccines studies

  **SARS-CoV Vaccines**       **Antigens**             **Vaccine formulations**                                                 **Dose, Time of vaccination**                       **Animal models**                                               **Challenge dose. Virus strains, Time after last vaccination, Route**     **Results**                                                                                                          **References**
  --------------------------- ------------------------ ------------------------------------------------------------------------ --------------------------------------------------- --------------------------------------------------------------- ------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------- -------------------------------------------
  Whole Inactivated Vaccine   Inactivated              SARS-CoV FRA (*b*-propiolactone) + MF59                                  5 μg at 0, 2, and 4 weeks, SC                       BALB/c                                                          10^4^ TCID50 SARS-CoV Urbani, IN                                          Protection, no virus detected in Lung and Nasal Turbinates                                                           [@B225] EID
                              Inactivated              SARS-CoV Tor2 (*b*-propiolactone) + Alum                                 50 μg at 0 and 4 weeks, SC                          6 week old 129S6/SvEv                                           10^6^ pfu SARS-CoV Tor2 at week 3, IN                                     Protection                                                                                                           [@B213] JGV
                              Double Inactive          SARS-CoV (Utah) formaldehyde and UV inactivation + Al(OH)3               0.08 -- 0.2 μg at week 0 and 2, SC                  6 -- 8 weeks CD1 mice                                           10^5^ TCID50 SARS-CoV Utah at week 3 or 11, IN                            Protection, no virus detected in lung and trachea                                                                    [@B224] Vaccines
                              Inactivated              SARS-CoV Tor2 (*b*-propiolactone) + Alum                                 50 μg at 0 and 4 weeks, SC                          8 -- 10 month old ferret                                        10^6^ pfu SARS-CoV Tor2 at week 3, IN                                     Weak protection, slight reduction of viral titer in lung, BAL and nasal wash, slight improvement in lung pathology   [@B212] JGV
                              Inactivated              SARS-CoV Urbina (*b*-propiolactone) + AS01B and AS03A                    0.15 -- 1.5 μg at week 0 and 3, IM                  BALB/c                                                          10^5^ TCID50 SARS-CoV Urbani at week 3, IN                                Protection, no virus detected in lung                                                                                [@B208] Viral Immunology
                              Inactivated              SARS-CoV Urbina (*b*-propiolactone) + AS01B and AS03A                    2.0 μg at week 0 and 3, IM                          4 -- 8 week old Golden syrian hamsters                          10^3^ TCID50 SARS-CoV Urbani at week 4 or 18, IN                          Partial protection, reduce viral titer in lung                                                                       [@B208] Viral Immunology
                              Double Inactive          SARS-CoV MA15 formalin and UV inactivated + Alum                         0.2 μg at week 0 and 3--4 week, footpad             6 -- 8 weeks old BALB/cAnNHsd                                   10^5^ PFU SARS-CoV MA15, SZ61and GD03 at week 5, IN                       Partial protection, reduce viral titer in lung and good protection from lethal challenge (MA15)                      [@B28] JVI
                              Double Inactive          SARS-CoV MA15 formalin and UV inactivated + Alum                         0.2 μg at week 0 and 3--4 week, footpad             12 -- 14 months old BALB/cAnNHsd                                10^5^ PFU SARS-CoV MA15, SZ61and GD03 at week 5, IN                       Weak protection, small drop in viral titer in lung, weak protection from leathal challenge (MA15)                    [@B28] JVI
  LAV                         SARS-CoV-ΔE (Urbani)     SARS-CoV-ΔE (Urbani)                                                     10^3^ TCID50 at 0 week, IN                          7 week old Golden syrian hamsters                               10^3^ TCID50 SARS-CoV Urbani and GD03 at week 4, IN                       Protection, no virus detected in lung                                                                                [@B127] JVI
                              SARS-C0V ExoN (MA15)     SARS-CoV-ExoN (MA15)                                                     10^2.5^ or 10^4^ PFU at week                        12 months old BALB/c                                            10^2.5^ TCID50 SARS-CoV MA15 at week 4, IN                                Complete survival from lethal challenge, no virus detected in lung                                                   [@B87] Nat Med
                              SARS-CoV ΔNSP16          SARS-CoV Δ2′-*O*-Methyltransferase                                       10^2^ PFU at week 0, IN                             10 weeks old BALB/c and C57BL/6                                 10^5^ PFU SARS-CoV MA15 at week 4, IN                                     Complete survival from lethal challenge, no viral titer performed                                                    [@B165] JVI
                              SARS-CoV ΔNSP16/ExoN     SARS-CoV Δ2′-*O*-Methyltransferase and ExoN mutation                     10^2^ PFU at week 0, IN                             12 months old BALB/c                                            10^5^ PFU SARS-CoV MA15 at week 4, IN                                     Complete survival from lethal challenge, no virus detected in lung                                                   [@B163] JVI
  Subunit                     subunit nS Sf9           SARS-CoV S (14-762) Urbani + QS21                                        10 μg at week 0, 4, and 8, SC                       6 weeks old BALB/c                                              10^5^ TCID50 SARS-CoV (Urbani) at week 4, IN                              Protection, reduce viral titer in lung and nasal turbinates                                                          [@B26] Virology
                              Ectodomain Sf9           SARS-CoV S ectodomain (Urbani) + Protollin                               10 or 30 μg at week 0, 2 and 5, IN                  ∼ 1 year old BALB/c                                             5x10^4^ TCID50 SARS-CoV Urbani at week 1, IN                              Protection, reduce viral titer in lung                                                                               [@B102] Vaccines
                              Subunit RBD219 CHO       SARS-CoV RBD (318-536)Tor2 + Freund                                      20 μg at week 0 and 10 μg at week 3 and 6, SC       4 -- 6 weeks old BALB/c                                         5x10^5^ TCID50 SARS-CoV GZ50 at 10 day, IN                                Protection, no virus detected in lung                                                                                [@B72] viral immunology
  Subunit Trimer              Spike trimer             SARS-CoV RBD Spike Trimer Urbani + Alum                                  50 μg at week 0, 3, and 6, SC                       5 weeks old Golden syrian hamsters                              10^3^ TCID50 SARS-CoV Urbani at week 2, IN                                Protection, no virus detected in lung and reduce pneumonitis                                                         [@B112] Vaccines
  VLP                         MHV-S VLP                SARS-CoV S in MHV + Alum                                                 2 μg at 0 and 4 weeks                               6 -- 8 week old BALB/c                                          10^6^ TCID50 SARS-CoV at week 8, IN                                       Protect, no virus detected in Lung                                                                                   [@B147] Vaccine
                              Flu M1-S                 SARS-CoV S Urbani in influenza M1 + Al(OH)3                              0.8 or 4 μg at week 0 and 3, IM                     6 -- 8 weeks old BALB/c                                         2xLD50 mouse adapted SARS-CoV V2163 at week 3, IN                         Complete survival from lethal challenge, no virus detected in lung                                                   [@B145] Vaccines
  DNA                         Plasmid *S*-Ectodomain   Plasmid expressing SARS-CoV S ΔCD or ectodomain (Urbani)                 25 μg at week 0, 3, and 6, IM                       6 -- 8 week old BALB/c                                          10^4^ TCID50 SARS-CoV Urbani, at Day 30, IN                               Protection, reduce viral titer in lung and nasal turbinates                                                          [@B268] Nature
  Vector                      BHPIV3 SARS-S            SARS-CoV S or SME Urbani in parainfluenza virus type 3 vector (BHPIV3)   10^6^ TCID50 at 0 week, IN                          Golden syrian hamsters                                          10^3^ TCID50 SARS-CoV Urbani at week 4, IN                                Protection, no virus detected in lung                                                                                [@B31] PNAS
                              BHPIV3 SARS-S            SARS-CoV S Urbani in parainfluenza virus type 3 vector (BHPIV3)          10^6^ TCID50 each at 0 week, IN and IT              African green monkeys                                           "A large dose of SARS-CoV" at week 4, IN                                  Protection, no virus detected in lung                                                                                [@B32] Lancet
                              MVA-SARS-S               SARS-CoV S Urbani in MVA                                                 10^7^ at 0 and 4 week, IN                           BALB/c                                                          10^4^ TCID50 SARS-CoV Urbani, at week 8, IN                               Protection, reduce viral titer in lung and nasal turbinates                                                          [@B25] PNAS
                              MVA-SARS-S               SARS-CoV S Urbani in MVA                                                 10^7^ at 0 and 4 week, IM                           BALB/c                                                          10^4^ TCID50 SARS-CoV Urbani, at week 8, IN                               Protection, reduce viral titer in lung and nasal turbinates                                                          [@B25] PNAS
                              MVA-SARS-S               SARS-CoV S and N Tor2 in MVA                                             10^8^ pfu at 0 and 5 × 10^7^ at 2 week, IP and SC   Ferret                                                          10^6^ pfu SARS-CoV Tor2 at week 4, IN                                     No protection according to viral RNA in lung, Ab induction                                                           [@B54] Vaccines
                              VSV-S                    VSV-SARS-S Urbani                                                        1.4 × 10^4^ pfu at week 0, IN                       BALB/c                                                          10^4^ TCID50 SARS-CoV Urbani at month 1 and 4, IN                         Protection, no virus detected in lung and nasal turbinates                                                           [@B114] Virology
                              hAd5 (N+S)               Human Adenovirus 5 with S + Ad5 N gene                                   3 × 10^8^ pfu each at 0 and 4 weeks, IM             6 week old 129S6/SvEv                                           10^6^ pfu SARS-CoV Tor2 at week 3, IN                                     No protection despite strong IgG1, IgG2a Ab induction and high IFN-g secretion                                       [@B213] JGV
                              hAd5 (N+S)               Human Adenovirus 5 with S + Ad5 N gene                                   3 × 10^8^ pfu each at 0 and 4 weeks, IN             6 week old 129S6/SvEv                                           10^6^ pfu SARS-CoV Tor2 at week 3, IN                                     Partial protection, Induction of IgA                                                                                 [@B213] JGV
                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  **MERS-CoV Vaccines**       **Antigens**             **Vaccine formulations**                                                 **Dose, Time of vaccination**                       **Animal models**                                               **Challenge dose. Virus strains, Time after last vaccination, Route**     **Results**                                                                                                          **References**
                                                                                                                                                                                                                                                                                                                                                                                                                                                   
                              VEEV-S                   SARS-CoV GD03 S in VEEV                                                  10^6^ IU at 0 week, boost 3 -- 5 weeks, footpad     4 -- 7 weeks old                                                10^5^ pfu SARS-CoV GD03 and Urbani at week 7 -- 8 and week 54, IN         Protection, no virus detected in lung                                                                                [@B62] PlOS Med
                              VEEV-S                   SARS-CoV GD03 S in VEEV                                                  10^6^ IU at 0 week, boost 3 - 5 week, footpad       \> 26 week old                                                  10^5^ pfu SARS-CoV GD03 and Urbani at week 7 -8 and week 54, IN           No protection                                                                                                        [@B62] PlOS Med
                              hAd5-S + AdC7-S          Human Adenovirus 5 with S + Chimpanzee AdC7 with S Tor2                  5 × 10^11^ VP/kg at 0 and 1 month, IM               18 -- 20 weeks old ferret                                       10^6^ pfu SARS-CoV Tor2 at not specify, IN                                Protection, reduce viral titer in lung and nasal turbinates                                                          [@B125] Vaccines
                              hAd5 (N+S)               Human Adenovirus 5 with S + Ad5 N gene                                   1 × 10^9^ pfu each at 0 and 4 weeks, IM             8 - 10 month old ferret                                         10^6^ pfu SARS-CoV Tor2 at week 3, IN                                     Inconclusive, control hAd5 shows non-specific protection                                                             [@B212] JGV
                              hAd5 (N+S)               Human Adenovirus 5 with S + Ad5 N gene                                   1 × 10^9^ pfu each at 0 and 4 weeks, IN             8 -- 10 months old ferret                                       10^6^ pfu SARS-CoV Tor2 at week 3, IN                                     Inconclusive, control hAd5 shows non-specific protection                                                             [@B212] JGV
  Whole Inactivaed Vaccine    Inactivated              MERS-CoV (γ-ray) + Alum or MF59                                          10^6^ TCID50 at week 0 and 3, IM                    hCD26/DPP4 transgenic mice                                      10^3^ TCID50 (100xLD50) MERS-CoV at week 3, IN                            Protection from virus replication, no virus detected in lung, increase lung pathology                                [@B7] Human vaccine and immuno therapy
                              Inactivated              MERS-CoV EMC/2012 (formaldehyde) + Alum and CpG                          1 μg at week 0, 4 and 8, IM                         14 -- 16 week old BALB/c transduced with hDPP4 by Ad5           10^5^ PFU MERS-CoV (EMC/2012) at week 2, IN                               Protection, no virus detected in lung                                                                                [@B64] Emerging Microbes and infection
  LAV                         MERSS-CoV ΔNSP16         MERS-CoV Δ2′-*O*-Methyltransferase EMC MA1                               10^6^ PFU at week 0, IN                             10 - 20 week old C57BL/6 288-330+/+                             10^6^ PFU MERS-CoV EMC MA1 at week 4, IN                                  Complete survival from lethal challenge, reduce viral titer in lung                                                  [@B162] msphere
  Subunit                     RBD                      MERS-CoV RBD S367-606 (EMC/2012) + alum                                  200 μg at week 0 and 100 μg at week 8 and 25, IM    Rhesus Macaque                                                  6.5x10^7^ TCID50 MERS-CoV (EMC/2012) at week 2, IN                        Partial protection, reduce viral titer in lung and trachea                                                           [@B129] EBioMedicine
                              NTD                      MERS-CoV NTD S18-353 (EMC/2012) + alum and CpG                           5 or 1 μg at week 0, 4 and 8, IM                    16 -- 18 weeks old BALB/c transduced with hDPP4 by Ad5          10^5^ PFU MERS-CoV (EMC/2012) at week 2, IN                               Partial protection, reduce lung and trachea pathologies, no viral titer information                                  [@B108] Vaccines
                              S ectodomain             MERS-CoV EMC/2012 S ectodomain + Alum and CpG                            1 μg at week 0, 4 and 8, IM                         14 -- 16 week old BALB/c transduced with hDPP4 by Ad5           10^5^ PFU MERS-CoV (EMC/2012) at week 2, IN                               Protection, reduction in lung viral titer                                                                            [@B64] Emerging Microbes and infection
                              RBD-Fc                   MERS-CoV RBD S377-588 Fc (EMC/2012) + MF59                               10 μg at week 0, 3, and 6, SC                       4 -- 6 weeks old BALB/c transduced with hDPP4 by Ad5            10^5^ PFU MERS-CoV (EMC/2012) at week 2, IN                               Protection, no virus detected in lung                                                                                [@B277] Cellular and molecular immunology
                              RBD-Fc                   MERS-CoV RBD S377-588 Fc (EMC/2012) + Addavax                            10 μg at week 0 and 4, IM                           hCD26/DPP4 transgenic mice                                      10^3^ TCID50 (100xLD50) MERS-CoV (EMC/2012) at week 4, IN                 Complete survival from lethal challenge, no virus detected in lung                                                   [@B181] Vaccines
                              S1                       MERS-CoV ENgland1 S1 + Advax HCXL or Sigma oil-in-water emulsion         400 μg at week 0, 4 and 15, IM                      dromedary camel                                                 10^7^ TCID50 MERS-CoV (EMC/2012) at ∼week 4, IN                           Protection, reduce viral titer in lung and nasal turbinate                                                           [@B3] Virus
                              S1                       MERS-CoV ENgland1 S1 + Advax HCXL or Sigma oil-in-water emulsion         400 μg at week 0, 4, and 15, IM                     Alpaca                                                          10^7^ TCID50 MERS-CoV (EMC/2012) at ∼week 4, IN                           Protection, no virus detected in lung, nasal turbinate and nasal swabs                                               [@B3] Virus
  Subunit Trimer              RBD Trimer               MERS-CoV RBD-Fd (Trimer) + alum                                          5 μg at week 0 and 4, IM                            hCD26/DPP4 transgenic mice                                      10^4^ TCID50 MERS-CoV (EMC/2012) at week 12, IN                           Complete survival from lethal challenge, no viral titer performed                                                    [@B231] Virology
  VLP                         S nanoparticles          MERS-CoV Jordan S nanoparticle + Matrix M1                               10 μg at week 0 and 3, IM                           15 -- 17 weeks old BALB/c transduced with hDPP4 by Ad5          2.5 × 10^3^ PFU MERS-CoV (Jordan) at week 4, IN                           Protection from chalenge, no virus detected in lung                                                                  [@B48] Vaccines
                              BNSP333-S                MERS-CoV S1 Jordan fused with rabies virus G protein VLP                 10 μg at week 0, 1, and 3, IM                       15 -- 17 weeks old BALB/c transduced with hDPP4 by Ad5          2.5 × 10^3^ PFU MERS-CoV (Jordan) at week 4, IN                           Protection, no virus detected in lung                                                                                [@B260] JVI
  DNA                         Plasmid S-protein        Plasmid expressing MERS-CoV S1 (Al-Hasa_1\_2013)                         0.5 or 2 mg at week 0, 3 and 6, IM                  Rhesus macaques                                                 7 × 10^6^ TCID50 MERS-CoV (EMC/2012) at week 5, IT, IN, oral and ocular   Protection, reduce viral titer in lung, reduce clinical pathology                                                    [@B177] STM
                              Plasmid S1               Plasmid expressing MERS-CoV S1 (Al-Hasa_15_2013)                         100 μg at week 0, 3 and 6, IM                       14 - 16 week old BALB/c transduced with hDPP4 by Ad5            10^5^ PFU MERS-CoV (EMC/2012) at Day 18, IN                               Protection, reduce viral titer in lung                                                                               [@B43] Vaccines
  Vector                      MVvca2 S or soluble S    Recombinant measles virus with MERS-CoV (EMC/2012) S or soluble S        10^5^ TCID50 at week 0 and 4, IP                    6 -- 12 week old IFNAR−/− CD46Ge transduced with hDPP4 by Ad5   7 × 10^4^ TCID50 MERS-CoV (EMC/2012) at week 6, IN                        Protection, reduce viral titer in lung, reduce lung pathology                                                        [@B157] JVI
                              ChAdOx1 MERS             ChAdOx1 with MERS-CoV *S*-protein (EMC/2012)                             10^8^ IU at week 0, IN or IM                        hCD26/DPP4 transgenic mice                                      10^4^ TCID50 MERS-CoV (EMC/2012) at week 4, IN                            Complete survival from lethal challenge, no virus detected in lung, reduce lung pathology                            [@B175] npj
                              MVA-MERS-S               MVA with MERS-CoV *S*-protein                                            10^6^, 10^7^, or 10^8^ PFU at week 0, IM or SC      14 -- 16 week old BALB/c transduced with hDPP4 by Ad5           7 × 10^4^ TCID50 MERS-CoV (EMC/2012) at week 6, IN                        Protection, reduce viral RNA genome in lung, reduce lung pathology                                                   [@B246] JVI
                              rAd5-S1/F/CD40L          hAd5 with MERS-CoV S1 trimer fused with CD40L                            10^9^ PFU at week 0 and 4, IM                       hCD26/DPP4 transgenic mice                                      10^3^ TCID50 (100xLD50) MERS-CoV (EMC/2012) at week 4, IN                 Complete survival from lethal challenge, no virus detected in lung, reduce lung pathology                            [@B98] JID

Selection criteria: Only animal studies with a challenge model are included. LAV, live attenuated vaccine; VLP, virus like particle; RBD, receptor binding domain; IM, intramuscular; IN, intranasal; SC, subcutaneous; IP, intraperitoneal.

Current Vaccine Strategies {#S2.SS2}
--------------------------

Inactivated vaccines are the quickest option for vaccine development in an outbreak situation. Multiple chemical and physical methods have been applied singly or in combination to inactivate CoVs, including β-propiolactone, formalin, formaldehyde and UV. While multiple studies have shown the efficacy of inactivated vaccines in hamster, ferret and multiple mouse challenge models ([@B225]; [@B213], [@B212]; [@B224]; [@B208]), one study suggested a potential vaccine enhanced pathologies ([@B28]). In this study, double inactivation (DIV) of SARS-CoV using formalin and UV+alum elicits a Th2 skewed response and is only partially protective to young mice (6--8 weeks-old) and not protective to experimentally aged mice (12--14 weeks-old) ([@B28]). Furthermore, upon challenge, DIV vaccinated mice show increased infiltration of eosinophils, neutrophils and other inflammatory cell populations in the lung, likely due to the N specific immune response ([@B28]). Further studies have suggested that by replacing alum with TLR agonists such as Poly I:C, Poly U or LPS as adjuvants, the skewed Th2 responses can be alleviated and may reduce the infiltration of eosinophils in the lung ([@B106]).

Gamma-ray inactivated whole MERS-CoV (WIV) with alum or M59 also suffers from the Th2 skewed immune response and pulmonary eosinophilia upon challenge, suggesting a potential risk of using inactive virus for CoV vaccination ([@B7]). Interestingly, formaldehyde inactivated MERS-CoV co-administered with alum and CpG shows a more balanced Th1/Th2 response and is able to protect mice from a challenge model (Ad5 transduced hDPP4) with reduction in lung viral titer and improved lung pathology. There is no observable vaccine-induced lung pathology or infiltration of eosinophils upon challenge ([@B64]). The difference in vaccine outcomes indicates an incomplete understanding of the effect of adjuvants on the inactivated SARS and MERS-CoV vaccines. In respiratory syncytial virus (RSV) vaccines, formalin inactivated vaccines presents the post-fusion form predominately and fail to elicit protective immune responses. Whether the same phenomenon exists in inactivated CoV is still unknown, although it could explain the discrepancy between reports. The inconsistent results from different vaccine models also underscores the host genetic elements affecting vaccine outcome. Nevertheless, inactivated vaccine is still one of the most straightforward methods for vaccine development and has the quickest response time in an outbreak situation.

Live attenuated viral vaccines are the closest mimic of natural infection and generally elicit strong B and T cell responses ([@B280]). Multiple strategies have been used to genetically attenuate SARS-CoV and MERS-CoV by either deleting or mutating structural, non-structural or accessory proteins. Intranasal immunization of a SARS-CoV lacking E protein (rSARS-CoV-ΔE) has shown complete protection from pulmonary replication in a Golden Syrian hamster model ([@B127]). A similar virus has been generated in the MERS backbone, creating a conditional mutant that requires trans expression of E for productive replication ([@B13]). Mutations of the DEDD motif of the 3′ to 5′ exonuclease (ExoN-nsp14) "proof-reading protein" on a mouse-adapted SARS-CoV attenuated the virus both *in vitro* and *in vivo*. A single intranasal immunization is able to elicit strong nAbs (\>6-fold protective titers) and completely protect against lethal challenges in an aged mouse model (12 months-old BALB/c) ([@B87]). Mutations in the nsp 16 (NSP16), a 2′*O*-methyltransferase, in both SARS-CoV and MERS-CoV have also been shown to attenuate the viruses and to protect BALB/c and CRISPR-Cas humanized DPP4-288-330 mice from lethal challenge ([@B165], [@B162], [@B163]). Moreover, these attenuation strategies can be multiplexed, leading to highly stable live attenuated vaccines with limited capability to undergo recombination and reversion repair ([@B88]; [@B163]). Although the live attenuated vaccine is effective in small animal models, there remain safety concerns about potential revertants and recombination with natural CoVs which hinders their usage in the clinical setting. Furthermore, live attenuated vaccines often require greater time for development and safety testing which lessens utility in an outbreak situation.

Protein-based subunit vaccines are considered the safest format of vaccine. However, the low immunogenicity of subunit vaccines dictates a heavily reliance on adjuvants. Different forms of the *S*-protein, including the S1 RBD, RBD-Fc (RBD with human IgG Fc fusion), and N-terminal domain (NTD), have demonstrated various degrees of nAb responses and protection in multiple animal models including non-human primates (NHP) ([@B129]; [@B277]; [@B108]; [@B251]; [@B64]; [@B181]; [@B3]). For instance, the SARS-CoV S1 subunit vaccine produced from sf9 cells and with the adjuvant saponin or protollin are able to reduce lung viral titer in young or aged mice after challenge, respectively ([@B26]; [@B102]). An RBD subunit of SARS-CoV produced from Chinese hamster ovarian (CHO) cells with Freund's adjuvant is able to protect young BALB/c mice from infection ([@B72]). MERS-CoV-S1 with adjuvants MF59 or Advax HCXL is able to protect alpacas and dromedary camels against MERS-CoV challenge ([@B3]). Adjuvant selection can affect the vaccine outcome, and combinations of adjuvants can have synergistic effects on the strength of the response. For instance, rRBD with adjuvants alum and CpG ODN together elicits a stronger humoral and cellular T cell response ([@B128]). Additionally, rNTD with alum is able to reduce lung pathology in a non-lethal MERS-CoV challenge ([@B108]). Instead of adjuvants alone, immune enhancers such as an Fc fragment, which increases the protein half-life when fused with the RBD, can also elicit a stronger IgG nAb and cellular immune response in multiple experimental animals ([@B71]; [@B154]; [@B234]; [@B181]). RBD-Fc fusion subunit vaccine is able to protect a lethal challenge of MERS-CoV in adenovirus transduced hCD26/DPP4 mice ([@B277]; [@B251]). While a large amount of work concerning the subunit vaccines has been done in conjunction with different adjuvants, the effect of each adjuvant is not well understood and multi-adjuvant systems (combinatorial admixes) have not been rigorously tested. A more systematic method of studying the effect of different adjuvants on CoV vaccines will be valuable for vaccine development, perhaps using genetic reference populations that more accurately phenocopy human genetic variation ([@B133]).

Trimeric forms of the *S*-protein and RBD have been developed using the T4 trimerization domain to mimic the native conformation of the spike RBD ([@B112]; [@B231]). The trimeric RBD antigens are able to elicit a robust nAb response and protect 80% of hDPP4 transgenic mice from lethal MERS-CoV challenge, although most animals still experienced slight weight loss ([@B231]). Alternatively, the MERS-CoV *S*-protein has been structurally designed to remain in perfusion state by mutating V1060 and L1061 at the tip of the central helix to proline (S-2P) ([@B122]; [@B186]). The MERS S-2P protein retains the receptor binding properties of the wild-type S and elicits nAbs against at least 3 different S domains, including RBD, NTD, and S2. Intramuscular injection of the MERS S-2P elicits nAb responses in mice comparable to the monomeric S1 and trimeric *S*-protein antigens. ([@B186]).

Similar to subunit vaccines are the viral like particle (VLP) and nanoparticle vaccines. VLP and nanoparticles provide multivalent binding similar to actual viruses without the potential safety concerns. In SARS-CoV, multiple systems were used to generate *S*-protein VLPs, including the mouse hepatitis virus (MHV) and influenza matrix 1 (M1). In the chimeric MHV system, the SARS-CoV protein is co-expressed with the MHV E, M and N proteins to produce MHV-S VLP. Mice vaccinated with the MHV-S VLP and alum have inhibited viral replication in lung after a homologous strain challenge ([@B147]). Instead of using MHV structural proteins, the influenza system express the SARS-CoV *S*-protein with influenza virus M1 proteins in Sf9 cells to create the M1-S VLP. Immunization of M1-S VLP with aluminum hydroxide can protect mice from a lethal challenge of SARS-CoV ([@B145]). In MERS-CoV, expression of S, E, and M proteins using the baculovirus system produces VLPs that are morphologically similar to the actual virus ([@B47]; [@B250]). Other methods such as CPV-based ([@B249]), rabies virus (MV)-based ([@B260]), ferritin-based ([@B214]), and *S*-protein aggregates ([@B47]) are all able to elicit immune responses and reduce viral replication in a mouse model when co-administered with Matrix M1 adjuvant ([@B48]). Although all show different degree of immune response in animal, only one study showed a reduction of viral titer *in vivo* via an adenovirus transduced hCD26/DPP4 mouse model ([@B48]).

Clinical Trials for SARS- and MERS-CoV Vaccines {#S2.SS3}
-----------------------------------------------

A finished phase 1 clinical trial for a SARS-CoV vaccine is a DNA vaccine that encodes the ectodomain of the SARS-CoV *S*-protein (NCT00099463). DNA vaccines rely on a continuous expression of antigen from a DNA plasmid that is injected intramuscularly and electroporated ([@B177]; [@B253]; [@B43]). In pre-clinical studies, 3 doses of an intramuscular plasmid injection was able to reduce viral titer in both lung and nasal turbinate in a BALB/c challenge model ([@B268]). The phase 1 trial showed favorable results; after 3 doses of DNA vaccine, all subjects showed CD4+ T cell responses, while 80% of subjects had nAbs and 20% of subjects showed CD8+ T cell responses. However, there has been no follow-up in the vaccine development, likely due to the end of the SARS-CoV outbreak ([@B158]). One MERS-CoV vaccine that is currently undergoing clinical trials (NCT03721718) is a DNA-based vaccine ([@B172]). GLS-5300 is a DNA vaccine based on a consensus full-length *S*-protein from MERS-CoV under the control of a CMV promoter. In preclinical studies, the vaccine was electroporated into mice, camel and rhesus monkeys three times within 1 month. The vaccine elicited B cell responses in all animals at 1 month post vaccination, and extracted IgG was able to neutralize multiple strains of MERS-CoV including England/2/2013, and Al-Hasa/1/2013 and, surprisingly, a group 1b CoV NL63 and a group 2a CoV HKU1 using the pseudotype neutralization assay ([@B177]). T cell responses were assessed in mice and monkeys, with both demonstrating T cell responses as indicated by the presence of IFN-γ, TNFα and IL2-secreting CD4+ and CD8+ T cells after peptide stimulation. Rhesus monkeys were also protected from challenge of the vaccine strain with lower viral titers and lung pathology as assessed by radiography and pathology studies ([@B177]). Currently, GLS-5300 has completed Phase I clinical trials (safety). Three doses (0.67, 2, and 6 mg) of GLS-5300 were electroporated intramuscularly at weeks 0, 4, and 12. Ninety-four percent of subjects were seroconverted and nAbs were detected in 50% of the individuals. Seventy-six percent of subjects developed T-cell responses against peptides derived from MERS-CoV *S*-proteins ([@B172]). Other than a full *S*-protein DNA vaccine, different designs also show promising results in preclinical mouse models. Notably, a DNA vaccine composed of only the S1 domain showed efficacy when paired with different adjuvants ([@B43]). Hybrid strategies using a DNA vaccine paired with a protein booster also showed promising results in eliciting more balanced Th1 and Th2 responses ([@B253]; [@B10]).

Vector-Based Vaccines {#S2.SS4}
---------------------

Two out of the three clinical trials for MERS vaccines are vectorized vaccines. Viral vector-based vaccines have multiple advantages over the generic protein or DNA-based subunit vaccines. Firstly, as viral vectors utilize a defined viral entry mechanism, they are more efficient at delivering DNA into cells. Second, the vector itself can serve as an adjuvant which in turn elicits both B- and T-cell responses ([@B242]). Finally, a wide variety of vector systems including measles viruses ([@B157]; [@B27]), Venezuelan equine encephalitis virus (VEEV) replicon system ([@B62]; [@B4]; [@B283]), adeno-associated virus (AAV) ([@B73]), parainfluenza type 3 (BHPIV3) ([@B31]; [@B32]), human and chimpanzee adenovirus (hAd5 and ChAdOx1) ([@B213], [@B212]; [@B125]; [@B120]; [@B91]; [@B98]) and modified vaccinia virus Ankara (MVA) ([@B25]; [@B54]; [@B114]; [@B93]) have been previously established for use as vaccine platforms for multiple infectious diseases. Herein, we will focus on the three systems that have been or are currently under clinical trial; all others are summarized in [Table 1](#T1){ref-type="table"}.

Replication-defective adenovirus vectors are one of the most effective choices to deliver vaccine antigens. Human adenovirus 5 (hAd5) and enteric adenovirus type 41 (Ad41) have both been used to deliver MERS-CoV S or S1 proteins. Intramuscular inoculation of the vaccine elicits both B-cell (nAb titer) and T-cell (IFN-γ secreting splenocytes and pulmonary lymphocytes) responses ([@B91]). However, pre-existing nAbs against hAd5 and 41 in the human population have limited their usage to dromedary camels instead of humans ([@B44]). The pre-existing nAb problem against hAd5 can be circumvented by using a chimpanzee adenovirus. One such platform is ChAdOx1, wherein the adenovirus E1 gene is replaced by a MERS-CoV *S*-protein with an N-terminal secretion peptide from human plasminogen activator (tPA) driven by a CMV promoter. Intramuscular inoculation of the vector successfully elicits nAbs against *S*-protein as quickly as 14 days post infection. Splenic CD8+ T-cells secreting IFN-γ, TNF-α and IL-17 are also present at 28 days post infection ([@B12]). A single intranasal or intramuscular inoculation of ChAdOx1-MERS is able to protect a human DPP4 transgenic mouse from lethal challenge by MERS-CoV, and the vaccine ([@B175]) is currently under phase 1 clinical trial (NCT03399578). CHAdOx1 has also shown effective protection for Rift Valley Fever Virus in dromedary camels ([@B257]).

The modified vaccinia virus Ankara (MVA) vector is another effective platform for MERS-CoV vaccine development. *S*-protein is inserted into the MAV genome at deletion site III driven by the viral P11 promoter. After a single intramuscular injection, BALB/c mice produce nAbs against both the RBD and S2, as tested *in vitro* ([@B223]). A follow-up study identified IFN-γ secreting splenocytes after peptide S291 stimulation at 56 days post infection, suggesting the vaccine is able to elicit memory CD8+ T cell responses. The vaccine is also able to protect a hDDP4-transduced BALB/c mouse model. RNA genomes in the lungs and lung pathology are drastically reduced compared to mock vaccination ([@B246]). The MAV based MERS-CoV vaccine has also been tested on dromedary camels and elicits induction of nAbs in sera and nasal swabs. Vaccinated camels also show reduced RNA genomes and gross pathology. The Phase I clinical trial has just been completed and the results are pending (NCT03615911).

Antivirals {#S3}
==========

The Challenge for Treatment Windows {#S3.SS1}
-----------------------------------

The average incubation period for SARS-CoV and MERS-CoV is around 5 days ([@B288]; [@B61]) and the main site of viral replication is the lower respiratory tract ([@B49]; [@B195]). At 7--10 days after symptomatic onset, viral RNA titer peaks in the upper respiratory tract ([@B69]; [@B49]). For terminal cases, disease lasts for an average of 12 days post symptomatic onset for MERS-CoV and 24 days for SARS-CoV ([@B288]). Interestingly, severe symptoms begin as the viral titer is decreasing, suggesting that severe CoV pathogenesis is due to immune complications and the inability to resolve inflammation ([@B191]; [@B256]). SARS-CoV upregulates pro-inflammatory cytokine production in the lung, including IL1, IL6, IL8, IL10, CXCL10 and TNF-α production ([@B24]). Compared to SARS-CoV infected patients with mild diseases, patients with ARDS fail to induce interferon (IFN) expression and the subsequent IFN-stimulated genes (ISGs) that are indicative of adaptive immune responses ([@B34]; [@B24]). The inability to switch from an innate immune response to the adaptive immune response may lead to uncontrollable inflammation and severe end stage lung disease. Given the rapid progression of symptoms to terminal illness, there is only approximately a 1 week treatment window after the onset of symptoms for antiviral and medical intervention ([@B259]). This treatment window could further compromised by delays in virus diagnosis, causing a challenge for timely medical intervention administration when the virus titers and pathological symptom are relatively mild ([@B49]; [@B8]). Unlike humans, experimental animal models have a compressed disease course (\<7 days), and it is difficult to differentiate between early and late phase of infection. It would be beneficial for clinical studies to separate the early- (\<10 days) and late-phase (\>10 days) patients to determine differences in patient response between the groups.

The Challenge for Therapeutic Development {#S3.SS2}
-----------------------------------------

Despite of the presence of a 3′ to 5′ exoribonuclease (exoN) proofreading enzyme, their large genome size (28--30 kb) means that CoVs remain in the category of highly mutating viruses ([@B76], [@B75]; [@B65]). The high mutation rate poses a considerable challenge for antiviral development as drug resistant viruses could arise or already exist within the quasispecies in nature or from an infected individual ([@B30]). For instance, after a prolonged period of nAb or drug treatments, the CoV can acquire mutations which confer resistance to the therapeutics ([@B287]). The appearance of these "escape viruses" has been confirmed in multiple mouse model studies in well-contained laboratory settings as well as in nature ([@B179]; [@B237]; [@B103]; [@B109]; [@B235]; [@B230]; [@B123]). Fortunately, some of the mutations that confer drug resistance also compromise viral fitness and attenuate the virus ([@B63]; [@B5]). Another therapeutic intervention is the use of immune modulators, such as IFN-α2a/2b, IFN-β1b and corticosteroids in treating CoVs ([@B149]; [@B192]; [@B229]). Although multiple studies have shown efficacy of IFN-α2a/2b and IFN-β1b singly or in combination with off-labeled antivirals such as ribavirin, lopinavir (LPV) and ritonavir (RTV) in treating SARS- and MERS-CoV in mouse, rhesus monkey and marmoset models ([@B92]; [@B19]; [@B79]; [@B36]), clinical studies have shown inconclusive results ([@B173]; [@B171]). Currently, a randomized controlled trial is underway to determine the efficacy of a combination of LPV/RTV and IFN-β1b in treating MERS-CoV infection (NCT02845843).

Convalescent Plasma and Monoclonal Antibodies {#S3.SS3}
---------------------------------------------

Although there is no approved drug to treat severe CoV infection, multiple strategies have shown promising results in an experimental setting ([Figure 2](#F2){ref-type="fig"}). Convalescent plasma (CP) is derived from patients who have recovered from SARS-CoV and MERS-CoV infection and contains high titer nAbs ([@B101]; [@B9]; [@B219]). Some data suggest that CP use against SARS-CoV infection is safe and, when administered at an early time point, may reduce mortality ([@B156]). CP neutralizing titers \> 1:80 may have a positive impact on infected MERS-CoV patients with respiratory failure ([@B124]). Unfortunately, CP from convalescent patients is difficult to obtain in large quantities and the Ab titer is too low to have beneficial effects, making it difficult to be used as a main stream therapeutic or for clinical testing ([@B15]). As such, no systematic, well-designed clinical trial has formally demonstrated the efficacy of CP in emerging CoV infection. Rather, a clinical trial for testing CP against MERS-CoV infection was withdrawn prior to patient enrollment (NCT02190799).

![Schematic of the CoV replication cycle and key steps for antiviral targets. White text boxes indicate the subtype of antivirals that work either extracellularly or intracellularly. Different steps of the CoV replication cycle are illustrated in cartoon form, including receptor binding, membrane fusion, viral RNA replication, sub-genomic RNA transcription and translation.](fmicb-11-00658-g002){#F2}

Although CP from convalescent patients is difficult to obtain, the active component (neutralizing antibodies) can be isolated and subsequently produced in large quantity using recombinant technology ([@B50]). Passive infusion of neutralizing monoclonal Abs (mAbs) has been used for several diseases with success, including RSV and Ebola virus ([@B86]; [@B289]). Numerous highly potent mAbs against SARS-CoV and MERS-CoV have been isolated by multiple groups all over the world using different methods such as phage display and direct B cell cloning from immunized animals or convalescent patients ([@B228]; [@B239]; [@B90]; [@B244]; [@B285]; [@B50]). While all of them shows protecting activity *in vitro*, several of them have also shown efficacy in mouse and NHP models ([@B236]; [@B110]; [@B42]; [@B245]; [@B60]; [@B267]). The plethora of potent nAbs have also provided insight into the major antigenic sites on which vaccine development should focus. A list of mAbs that show efficacy *in vivo* against SARS-CoV and MERS-CoV are summarized in [Table 2](#T2){ref-type="table"}. Due to the differences in testing conditions, direct comparison of mAb efficacy should be avoided. Multiple comprehensive review articles on the subject can also be found ([@B197]; [@B53]; [@B267]).

###### 

Summary of SAR-CoV and MERS-CoV neutralizating antibodies.

  **SARS mAbs**   **Epitopes**      **Origins**                                                        **Animal models**                                      **Treatment timing, Routes**                        **Dose, route of infection, Strains**                  **Results**                                                           **References**
  --------------- ----------------- ------------------------------------------------------------------ ------------------------------------------------------ --------------------------------------------------- ------------------------------------------------------ --------------------------------------------------------------------- ------------------
  S3.1            Spike             EBV transformated B cell from SARS patient                         8 weeks old BALB/c                                     24 h pre-infection, prophoylatic, IP                10^4^ TCID50, IN, Urbani                               Reduce viral titer (lung and nasal turbinates)                        [@B239]
  80R             RBD               Phage display on naive human antibody library                      16 weeks old BALB/c                                    24 h pre-infection, prophoylatic, IP                10^4^ TCID50, IN, Urbani                               Reduce viral titer (lung)                                             [@B228]
  m396            RBD               Naive human antibody library                                       8 week old BALB/c                                      24 h pre-infection, prophoylatic, IP                10^5^ TCID50, IN, Urbani, GD03, SZ16                   Reduce viral titer (lung)                                             [@B285]
  S230.15         RBD               EBV transformated B cell from SARS patient                         8 weeks old BALB/c                                     24 h pre-infection, prophoylatic, IP                10^5^ TCID50, IN, Urbani, GD03, SZ16                   Reduce viral titer (lung)                                             [@B285]
                                                                                                       12 months old BALB/c                                   24 h pre-infection, prophoylatic, IP                10^6^ PFU, IN, Urbani, GZ02, SZ16                                                                                            [@B209]
                                                                                                                                                              Co-administration, IN                               10^6^ PFU, IN, GZ02                                    Not conclusive, reduce titer                                          
                                                                                                                                                              1, 2, and 3 days post-infection, theraputic         10^6^ PFU, IN, GZ02                                    Not protective                                                        
  CR3014          RBD               Naive human antibody library                                       Ferret                                                 24 h pre-infection, prophoylatic, IP                10^4^ TCID50, IT, HKU-39849                            Reduce viral titer (lung), no lung lesion                             [@B244]
                                                                                                                                                              Co-administration                                   10^3^ and 10^4^ TCID50, IT, HKU-39849                  Reduce viral titer (lung), reduce lung lesion                         [@B236]
                                                                                                       4 -- 6 weeks old BALB/c                                24 h pre-infection, prophoylatic, IP                10^5^ TCID50, IN, Urbani, GD03, SZ16                   Reduce viral titer (lung)                                             [@B90]
  m68             Spike (non-RBD)   Transgenic mice with human Ig gene immunized with SARS-CoV Spike   4 -- 6 weeks old BALB/c                                24 h pre-infection, prophoylatic, IP                10^5^ TCID50, IN, Urbani, GD03, SZ16                   Reduce viral titer (lung)                                             [@B90]
                                                                                                                                                                                                                                                                                                                                               
  **MERS mAbs**   **Epitopes**      **Origins**                                                        **Animal models**                                      **Treatment timing, Routes**                        **Dose, route of infection, Strains**                  **Results**                                                           **References**
                                                                                                                                                                                                                                                                                                                                               
  4C2             RBD               Mice immunized with MERS-CoV RBD                                   4 -- 6 weeks old BALB/c transduced with hDPP4 by Ad5   24 h pre-infection, prophylactic, IV                10^5^ PFU, IN, EMC/2012                                Reduce viral titer (lung)                                             [@B138]
                                                                                                                                                              24 h post-infection, theraputic, IV                                                                                                                                              
  Mersmab1        RBD               Mice immunized with MERS-CoV S1                                    hDPP4 transgenic mice                                  24 h post-infection, theraputic, IV                 10^4.6^ TCID50, IN, EMC/2012                           Reduce viral titer (lung)                                             [@B74]; [@B199]
  CDC2-C2         RBD               Single B cell cloning from MERS patients                           hDPP4 transgenic mice                                  24 h pre-infection, prophylactic, IP                10^6^ TCID50, IN, EMC/2012                             Reduce viral titer (lung)                                             [@B253], [@B252]
  G2              Spike (non-RBD)   Mice primed with MERS-CoV DNA and S1 protein                       hDPP4 transgenic mice                                  24 h pre-infection, prophylactic, IP                10^6^ TCID50, IN, EMC/2012                             Reduce viral titer (lung)                                             [@B253], [@B252]
  G4              S2                Mice primed with MERS-CoV DNA and S1 protein                       hDPP4 transgenic mice                                  24 h pre-infection, prophylactic, IP                10^6^ TCID50, IN, EMC/2012                             Reduce viral titer (lung)                                             [@B253], [@B252]
  MCA1            RBD               Phage display on naive human antibody library                      2 years old common marmosets                           24 h pre-infection, prophylactic, IP                5 × 10^6^ PFU, IT, EMC/2012                            Reduce viral titer (lung), weight loss and patholicical scores        [@B42]
                                                                                                                                                              2 or 12 h post-infection, theraputic, IP                                                                                                                                         
  LCA60           RBD               Single B cell cloning from MERS patients                           4 -- 6 weeks old BALB/c transduced with hDPP4 by Ad5   24 h pre-infection, prophylactic, IP                10^5^ PFU, IN, EMC/2012 and London1/2012               Reduce viral titer (lung), weight loss and pathology                  [@B51]
                                                                                                                                                              24 h post-infection, theraputic, IP                                                                                                                                              [@B51]
                                                                                                       2 -- 6 years old common marmosets                      24 h pre-infection, prophylactic, IP                5.2 × 10^6^ PFU, IN + IT + ocular + orally, EMC/2012   Moderately protective, reduce weight loss and pathology               [@B59]
  m336            RBD               Phage display on navie human antibody library                      hDPP4 transgenic mice                                  12h pre-infection, prophylactic, IP                 10^4^ TCID50, IN, EMC/2012                             reduce viral titer (lung), weight loss and patholicical scores        [@B269], [@B270]
                                                                                                                                                              12h post-infection, theraputic, IP                                                                                                                                               [@B7]
                                                                                                       5 -- 7 months old Australian white rabbit              24 h pre-infection, prophylactic, IV and IN         10^5^ TCID50, IN, EMC/2012                             Reduce viral RNA titer and lung inflammation                          [@B100]
                                                                                                       Common marmosets                                       6 h (IV) and 48 h (SC) post-infection, theraputic   5.2 × 10^6^ PFU, IN + IT + ocular + orally, EMC/2012   Moderately protective, reduce clinical diseases and gross pathology   [@B245]
  NbMS10          RBD               llama immunized with MERS-CoV RBD                                  hDPP4 transgenic mice                                  3 days pre-infection, prophylactic, IP              10^5.3^ TCID50, IN, EMC/2012                           Reduce weight loss and increase survival                              [@B279]
                                                                                                                                                              1 or 3 days post-infection, theraputic, IP                                                                                                                                       [@B279]
  HCAb-83         RBD               Dromedary camel immunized with MERS-CoV DNA and Spike protein      hDPP4 transgenic mice                                  6 h pre-infection, prophylactic, IP                 10^5^ TCID50, IN, EMC/2012                             Reduce viral titer (lung), weight loss and increase survival          [@B202]

IV, intravenous; IN, intranasal; IT, intratracheal; SC, subcutaneous; IP, intraperitoneal.

The binding epitopes of some well-studied mAbs provide valuable information for the neutralization mechanism and clinical implications. The majority of the mAbs target the RBD of the spike protein and prevent viral attachment. For example, mAb 80R is able to protect both *in vitro* and a 16 weeks old mouse model against SARS-CoV Urbani. However, it is unable to protect other strains due to amino acid variations in the RBD ([@B285]). On the other hand, S230.15 mimics receptor binding and triggers conformational changes in the SARS *S*-protein, completely protecting young and old mice from SARS-CoV challenge against multiple SARS-CoV, including Urbani, GD03 and SZ16 ([@B209]; [@B247]). Similar to SARS-CoV, the majority of mAbs targeting MERS-CoV, such as MERS-4, MERS-27 ([@B109]), m336 ([@B269], [@B270]) and humanized Ab 4C2 and 2E6 ([@B138]) all target the RBD and prevent the virus from binding to DPP4 with high potency. Interestingly, the mAb LCA60, isolated from a MERS-CoV infected patient, binds to RBD region and confers a broader neutralizing breadth, and is able to neutralize EMC2012 and London1 strains of MERS-CoV ([@B51]). Non-RBD targeting Abs G2 and G4 recognize the non-RBD region of S1 and S2 of MERS-CoV, respectively, showing cross-reactivity with multiple MERS-CoV variants and can protect hDPP4 transduced mice from challenge ([@B253], [@B252]). Two nanobodies isolated from camelids, NbMS10 and HCAb-83, show potency in hDPP4 transgenic mice by reducing weight loss and increasing survival after challenge. Interestingly, NbMS10 is able to protect mice as a therapeutic treatment 3 days post infection ([@B202]; [@B279]).

While many mAbs show promising properties for clinical use, two mAbs, REGN3048 and REGN3051, have completed phase 1 clinical trials (NCT03301090). These two mAbs were isolated from VelocImmune mice (expressing the variable regions of human Ig heavy and kappa light chain) immunized with MERS *S*-protein. Both mAbs show picomolar binding and inhibition of MERS pseudo particles transduction on Huh7 cells. REGN3048 is able to neutralize seven natural isolates of S variants, and IP injection of the mAb at 1 day before or after challenge reduces MERS-CoV RNA levels and lung pathologies in an hDPP4 transgenic mouse model ([@B187]). Given the acute severe phase that is associated with emerging CoV infections, a major hurdle for therapeutic antibodies and drugs is that early administration will likely prove most efficacious in clinical care, as has also been shown with influenza virus, Ebola virus and RSV immunotherapeutics ([@B183]; [@B200]; [@B82]; [@B206]).

Fusion and Viral Protease Inhibitors {#S3.SS4}
------------------------------------

Another critical step for CoV life cycle is membrane fusion and the subsequent release of the RNA genome for replication ([@B169]). Membrane fusion of CoVs is governed by the S2 domain of the *S*-protein ([@B186]; [@B238]). The S2 stem undergoes a major conformational change at the two heptad repeat regions (HR1 and HR2) to bring the host and viral membrane in close proximity for fusion pore formation ([@B274]; [@B248]). Multiple peptidomimetic fusion inhibitors that mimic the HR1 and HR2 of either SARS-CoV or MERS-CoV block the formation of the helical core and efficiently inhibit membrane fusion in the micromolar range ([@B83]; [@B150]; [@B266]). A single report has shown treatment of HR2 peptide 5h prior to MERS-CoV challenge in an Ad5-hDPP4 transduction mouse model reduces viral lung titer ([@B40]). The ability of these drugs to protect in lethal, high titer mouse models has yet to be proven.

CoV nsp3 and nsp5 genes encode the papain-like cysteine protease (PLpro) and 3C-like serine protease (3CLpro), respectively ([@B193]). PLpro cleaves the polyprotein and separates it into nsp1 to 4 while 3CLpro separates nsp4 to 16 ([@B286]; [@B96]). Since polyprotein processing is a critical step for CoV replication and transcription, viral proteases are high priority drug targets. Originally developed as HIV protease inhibitors, LPV and RTV have low micromolar activity against 3CLpro of both SARS-CoV and MERS-CoV *in vitro* ([@B265]; [@B57]). Testing in SARS-CoV infected patients has shown beneficial outcomes, including lowering the viral load, reducing the onset of ARDS, and lowering mortality rates with LPV and RTV (see nucleoside analogs) treatments ([@B45]). However, most of the drug studies were performed using retrospective control, sometimes with unbalanced gender ratios, and no treatment has proven efficacious in a randomized control trial ([@B287]). In a marmoset model, LPV/RTV treatment suggested a modest improvement in clinical and pathological outcome as well as reduction of viral load ([@B36]). However, due to different pathological consequences of treated and untreated group, viral titers were measured at different time points post-infection and all the experiments were performed with a relatively small number (*n* = 3) of single gender (male) animals ([@B36]). SARS-CoV and MERS-CoV infection has been shown to be heavily biased by age and gender, where elders and males experience more severe complications than females in clinical cases and mouse models ([@B116]; [@B11]; [@B39]). A single subject in a case study, an elderly patient, survived a severe MERS-CoV infection using a combination therapy of LPV/RTV, IFN1α, and ribavirin ([@B121]). An ongoing clinical trial in Saudi Arabia has begun to use a combination of LPV/RTV and IFNβ-1b for laboratory-confirmed MERS-CoV infection (NCT02845843). Given the importance of 3CLpro I viral life cycle, it is an attractive target for novel drug development ([@B126]).

Nucleoside Analogs and RdRp Inhibitors {#S3.SS5}
--------------------------------------

Ribavirin is a guanosine analog that targets RNA dependent RNA polymerases (RdRp) and has a broad efficacy against RNA viruses ([@B148]). The drug inhibits viral RNA synthesis and has shown efficacy against HCV and RSV ([@B56]). Ribavirin inhibits SARS-CoV and MERS-CoV replication at high concentration *in vitro* ([@B232]; [@B78]), However, ribavirin enhances viral replication in the mouse lung and prolongs viral persistence in a SARS-CoV mouse model ([@B18]). Although not effective as a monotherapy, ribavirin shows a synergistic effect against SARS-CoV and MERS-CoV when combine with IFN ([@B173]). In a rhesus macaque model, MERS-CoV infected monkeys show improvement after treating with ribavirin and IFN-α2b ([@B79]). Furthermore, ribavirin has been used in clinical settings during SARS-CoV and MERS-CoV outbreaks ([@B184]; [@B118]; [@B215]). While some studies report positive outcome after treatment with ribavirin + IFN, others suggest no significant improvement ([@B66]; [@B118]). Due to the variation in dosage and time of administration and the lack of control, the efficacy of using ribavirin in patients is inconclusive. Mechanistically, studies show that recombinant CoV with a deleted proof-reading exonucleases N (ExoN) shows higher sensitivity toward ribavirin. These results indirectly suggest that the low activity of ribavirin in CoV could be explained by the presence of a proofreading exonucleases N (ExoN, nsp14) which can excise the drug from the viral mRNA in CoVs ([@B221]; [@B80]).

Two nucleoside analogs, β-[D]{.smallcaps}-N4-Hydroxycytidine (NHC) and GS-5734 (remdesivir), have shown high efficacy against CoVs and are less sensitive to ExoN ([@B217], [@B218]; [@B5], [@B6]). NHC is a cytidine analog and has recently been shown to inhibit multiple viruses, including influenza virus, RSV and Ebola virus ([@B205]; [@B243]; [@B272]). It has micro-molar EC50 against both alpha and beta CoVs including SARS-CoV and MERS-CoV ([@B20]; [@B198]; [@B6]). Currently under clinical development for Ebola viruses, remdesivir is a nucleoside prodrug that is effective against multiple other RNA viruses including Nipah viruses, RSV, and CoVs ([@B146]; [@B217]). Remdesivir has sub-micromolar inhibition concentrations in a broad range of CoVs including SARS-CoV, MERS-CoV, and hCoV-NL63, as well as pre-pandemic bat-CoVs WIV1 and SHC014 in an *in vitro* human airway epithelial (HAE) model ([@B217]; [@B5]). Prophylactic administration (one day pre-infection) of remdesivir can mitigate disease by reducing the viral titer and lung pathology in lethal mouse models challenged with a mouse adapted SARS-CoV MA15. Remdesivir also shows therapeutic activity when administered early at one day post-infection (corresponding to 7--10 days after the onset of symptoms in human infection). However, treatment initiated two days post infection does not improve disease outcomes, although the murine disease model is more compressed than in humans ([@B217]). Importantly, remdesivir shows excellent prophylactic protection. Rhesus macaques are completely protected from MERS-CoV infection as scored by lung pathology and clinical score as well as inhibited viral growth. Therapeutic treatment 12-h post infection shows moderate improvement of clinical outcomes on NHPs ([@B58]). The parental nucleoside of remdesivir, GS-441524, has also shown to be effective for treating FIP, a disease caused by the α-CoV FIPV ([@B176]; [@B190]). Currently, NHC and remdesivir are the only broadly effective antiviral drugs against all SARS-like, MERS-like, human contemporary, and animal CoVs ([@B217]; [@B5]; [@B176]; [@B190]). Some antiviral drugs, such as chloroquine and T-705, also show efficacy *in vitro* and are under consideration for the current COVID-19 outbreak ([@B254]).

Host Factor Inhibitors and Immuno-Modulators {#S4}
============================================

Host Protease Inhibitors {#S4.SS1}
------------------------

Like all class I viral fusion proteins, CoV S glycoproteins require proteolytic cleavage by host proteases for membrane fusion and viral entry ([@B22]; [@B258]; [@B169]). Two cleavage events have been characterized in SARS-CoV and MERS-CoV. The first cleavage event separates the head (S1) and the fusion stem (S2) by cutting the S1/S2 junction ([@B168]). The second cleavage event occurs at the S2' site which is usually located immediately upstream of the fusion peptide ([@B21]). Multiple proteases have been shown to be involved in the cleavage events, including cathepsin-[L]{.smallcaps}, trypsin-like serine proteases, transmembrane serine proteases (TTSP) and proprotein convertases such as furin ([@B168]). Cathepsin-[L]{.smallcaps} inhibitors MDL28170 and SSAA09E1 block SARS-CoV pseudotyped particle infection in pre-treated 293T cells ([@B220]; [@B2]). While a peptidomimetic furin substrate, decanoyl-RVKR-chloromethylketone, has been shown to inhibit cleavage of MERS *S*-protein and block infection in multiple cell lines including normal human bronchial epithelial cells (NHBE), the *in vivo* potency of this approach is less certain ([@B84]; [@B167]; [@B159]).

Host Receptor Inhibitors {#S4.SS2}
------------------------

The blocking of receptor interactions is also a target of antiviral development. *N*-(2-aminoethyl)-1 aziridine-ethanamine (NAAE) blocks the interaction of SARS *S*-protein and ACE2 and inhibits S-mediated cell-to-cell fusion at millimolar concentrations ([@B104]). Similarly, an Ab blocking DPP4 can also inhibit MERS-CoV infection on primary bronchial epithelial cells ([@B201]). Importantly, the *S*-proteins of SARS-CoVs and MERS-CoV interact with their receptors outside of the active sites. Therefore, it would be of interest to develop inhibitors that do not affect the normal function of the host proteins but abolish the interaction of the CoV and receptor. Otherwise, long term inhibition of cellular proteins could have adverse effects on the host. For instance, inhibition of ACE2 may cause hypertension ([@B55]). Additionally, DPP4 is also responsible for multiple cellular functions including immune homeostasis, stem cell development, metabolism and T-cell regulation, and hence is not an ideal target for MERS-CoV infection ([@B160]; [@B185]).

Other Host Factor Inhibitors {#S4.SS3}
----------------------------

Another attractive target to inhibit CoV infection is the host metabolic pathways essential for CoV life cycles. CoVs replicate and transcribe in membrane-bound vesicles derived from the host's rough ER ([@B222]; [@B226]; [@B204]). MERS-CoV infection upregulates the biosynthetic pathways of multiple major lipogenic enzymes, including fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC) and HMG-CoA synthase (HMGCS) ([@B273]). AM580, which targets the major lipid biosynthesis transactivator n-SREBPs by interfering with and downregulating global lipid synthesis ([@B85]; [@B273]), inhibits the replication of multiple viruses including influenza virus, Zika virus, Enterovirus-A71 and MERS-CoV ([@B273]). Remarkably, MERS-CoV viral titer is reduced by 1,000- to 1,000,000-fold in the presence of AM580 in Huh7 cells or a human intestinal organoid model, respectively, and IP injection of AM580 for 3 days protects a human hDPP4 transgenic mouse model from MERS-CoV lethal challenge ([@B273]).

Immune Modulators {#S4.SS4}
-----------------

### Corticosteroids {#S4.SS4.SSS1}

SARS-CoV and MERS-CoV both cause lung inflammation and can progress into severe respiratory syndrome. Lacking direct antiviral effect, corticosteroids are an immune suppressor which is administrated to severe patients to alleviate lung inflammation. However, immune suppression could also facilitate viral replication. Therefore, corticosteroids are often administrated with antiviral or other immune modulators, such as IFN which can activate the immune system. Retrospective and prospective clinical studies have shown mixed observation in treating SARS-CoV and MERS-CoV patients with corticosteroids, IFN and ribavirin; while some showed a positive effect, others showed no difference.

### IFNs {#S4.SS4.SSS2}

SARS-CoV and MERS-CoV are able to suppress the induction of IFN synthesis by multiple mechanisms including inhibition of the IFN signal transduction pathways and evading detection by pattern recognition receptors (PRRs) and toll-like receptors (TLRs) ([@B81]; [@B139]; [@B174]). Therefore, external administration of IFN regiments could re-initiate the antiviral immune response in the host. During the SARS-CoV and MERS-CoV outbreaks, IFN-α, IFN-β, and IFN-γ were used in combination with various antiviral drugs, including LPV/RTV, ribavirin, corticosteroids and poly I:C ([@B287]). Although most of the clinical reports are positive, there is no consensus on the efficacy of IFN treatment in CoV infection. In animal model studies, IFN treatment is only effective when administrated at early time point for both SARS-CoV and MERS-CoV ([@B37], [@B38]). Furthermore, many of the clinical studies were confounded by multiple factors, including IFN dosages, combination of different antivirals, and the stage of infection ([@B171]). For instance, some studies targeted patients in the late stage of infection and show a worse survival rate than average ([@B14]; [@B119]). Based on multiple research reports, IFN-β shows the best efficacy in treating MERS-CoV infection ([@B35]; [@B97]; [@B121]). Currently, an open labeled, well controlled clinical study is aiming to test a set dose of LPV/RTV and IFN-β in treating MERS-CoV. The trial will probably provide insight into treating MERS-CoV infection in human population.

The Current Sars-CoV-2 Outbreak: a Challenge, an Opportunity {#S5}
============================================================

In December 2019, a new CoV outbreak started in Wuhan, China, a megacity with a population of 11 million. With an estimated basic reproduction number (R~0~) of 1.4 -- 2.5, SARS-CoV-2 quickly spread to every province in China and began to spread globally by the end of January 2020 ([@B284]), and was declared a worldwide pandemic in March 2020 by the World Health Organization. SARS-CoV-2 is capable of human-to-human transmission via either symptomatic or asymptomatic patients ([@B210]). The high mutation rate of CoVs and the possibility of super-spreader could potentiate the continuous spreading globally. Originally from bat, the SARS-CoV-2 Is 96% identical to a bat CoV designated RaTG13, isolated from a cave in Yunnan Province, China and belongs to the betacoronavirus 2b family, as does SARS-CoV ([@B284]). However, the *S*-proteins between SARS-CoV and 2019 nCoV share only 76--78% sequence similarity, rendering the current experimental vaccines and antivirals unlikely to be fully protective against SARS-CoV-2. As many group 2b SARS-like CoV have pre-epidemic potential, vaccines and countermeasures should be targeted against all of these strains to maximally protect against current and future threats to the global health and economy ([@B164], [@B166]).

After two CoV outbreaks in the last two decades, the public health officials and clinicians have experience in preventing spread and treating SARS-CoV-2 patients. Prompt communication between governments, quick quarantine procedures, and rapid viral detection assays have helped minimize SARS-CoV-2 cases in other countries thus far. Additionally, the scientific community has developed novel vaccine strategies and experimental antivirals to fight emerging CoV. New vaccines that specifically targeting SARS-CoV-2 are under development. Moderna had started a phase 1 clinical trial on an RNA vaccine (mRNA-1273) that encodes the prefusion stabilized form of SARS-CoV-2 *S*-protein (NCT04283461). Although there are no published studies of a RNA vaccine platform against CoV, the RNA platform has shown efficacy against multiple other viral infectious diseases including influenza, rabies, Flavivirus, and Ebola viruses in experimental animal models ([@B276]). Furthermore, pre-clinical data of the Zika virus mRNA vaccine (mRNA-1893) from Moderna has shown protection against Zika virus and abrogated maternal transmission of Zika virus in pregnant mice ([@B207]; [@B107]). Broad-spectrum antivirals which have shown efficacy against multiple CoVs have the potential to treat SARS-CoV-2 ([@B217], [@B218]). Given the high number of infected patients and at risk individuals, the current situation provides an opportunity to initiate clinical trials for (a) vaccine formulation designed to protect uninfected people, (b) broad spectrum antivirals to treat infected individuals and (c) formulation of immune modulators to alleviate clinical pathologies. A well-designed clinical trial could not only ameliorate the current situation, but also lay the foundation for future CoV outbreaks. Supported by a recent study on SARS-CoV-2 ([@B254]) and multiple research studies on SARS and MERS-CoVs ([@B217], [@B218]; [@B58]) and a single clinical report ([@B99]), remdesivir hold promises as treatment for SARS-CoV-2. The Chinese government has started a clinical trial using remdesivir for treating SARS-CoV-2 patients with mild to severe symptoms (NCT04252664, NCT04257656). On the clinical side, if time and resources permit, a centralized repository that records and digitizes infection cases would aid future medical and epidemiology studies through machine learning programs. Finally, the current situation also provides an opportunity to develop unconventional treatments, such as gene therapy, to target infectious diseases.

Unconventional Vaccines and Therapeutics -- Gene Therapies {#S6}
==========================================================

The field of gene therapy has undergone rapid growth in the last 10 years. Although mainly focused on rare genetic diseases, its potential in treating infectious diseases should not be discounted. One of the leading vectors, adeno-associated virus (AAV), has proven to be safe for human use and multiple AAV-based gene therapy drugs are approved by the FDA and the EMA ([@B117]; [@B115]). So far, the only report of use of AAV in CoV is as a DNA vaccine to deliver SARS-CoV spike protein for immunization ([@B73]). Given the recent developments in human antibody cloning technologies, AAV holds a promising potential to be a hybrid of vaccine and therapeutic which acts as a passive immunization vector to provide protection for the outbreak and as a therapeutic in early time scales.

AAV as a Vector for Passive Immunization Against Emerging CoV {#S6.SS1}
-------------------------------------------------------------

### The Vectors -- Safety {#S6.SS1.SSS1}

AAV is a non-pathogenic, non-enveloped, 4.7 kb single-stranded DNA virus belonging to the *Dependoparvovirus* genus within the family *Parvoviridae* ([@B52]). AAV infects a wide variety of animals, from bearded dragons to humans. Natural AAV isolates have different tissue tropisms in humans and can be reverse engineered to better fulfill various medical needs. To target SARS-CoV, MERS-CoV and other respiratory virus infections, a human airway tropic AAV is needed. Multiple reports have demonstrated that natural isolates AAV5 ([@B275]), AAV6 ([@B142]), and AAV9 ([@B1]) as well as engineered vectors AAV2.5 ([@B137]) and AAV2.5T ([@B77]) are able to transduce human lung epithelial cells, including primary human airway epithelial (HAE) cultures. Although there is a high prevalence of nAbs against AAVs in the human population, new technologies have been developed to engineer AAV to evade humoral immune responses ([@B241], [@B240]). These developments potentially allow for the delivery of CoV vaccines or immunotherapeutic directly to the mucosal compartments of the lung.

### The Package -- Flexibility {#S6.SS1.SSS2}

Passive immunization of AAV can be developed as a platform technology in which the nAb can be quickly exchanged to target specific pathogens. Multiple studies have shown passive immunization using AAV is effective against viral infectious diseases such as HIV, ([@B17]; [@B143]) Ebola, ([@B141]) influenza, ([@B16]; [@B132]), and others ([@B180]). The package for delivery is extremely flexible, from authentic immunoglobulins (IgG) to immunoadhesins (IA) to single chain variable fragments (scFv) to bi-specific antibodies ([@B178]). Furthermore, a combination of Abs, small antiviral peptides and immuno-modulators can be co-delivered at the same time to achieve multidimensional therapy. Although AAV-based passive immunization has not yet been tested as therapeutic, it could serve as a fast-acting prophylactic alternative to traditional vaccines.

### The Timing -- Quick {#S6.SS1.SSS3}

The most important aspect to control an outbreak is to reduce the spread by protecting the population from infection. However, there is a lag time between the beginning of an outbreak and the development of an effective vaccine in which the population is completely vulnerable. Prophylactic treatments, such as infusion of Abs and antivirals, could protect individual for a short duration. However, these prophylactic treatments require constant intake to stay effective and are toxic as well as financially impractical for long-term use ([@B94]). AAV-based passive immunization could perfectly fill the vacuum by protecting the population before the arrival of a vaccine. Since AAV is a platform technology, anti-viral packages can be swapped and tested quickly, within a month ([@B227]). After administration in animals, protection can be achieved in less than a week, faster than any vaccine strategies. In an influenza study, AAV9 delivery of IA via intranasal inoculation protected animals from lethal influenza challenges including H5N1, H1N1 and H1N1 1918 within 3 days of AAV administration ([@B140]). Unlike traditional gene therapy in which the transgene lasts for long periods of time, the natural turnover rate of airway epithelia means that the nAb introduction is not permanent, reducing the chance that the host will produce antibodies targeting the therapeutic antibody delivered by AAV (anti-drug antibody responses) ([@B180]). Therefore, AAV-based passive immunization is a quick and excellent option to deploy in an outbreak situation for emerging infectious diseases.

The Challenges {#S6.SS2}
--------------

AAV-based gene therapy has great potential for treating viral infectious diseases. However, there are multiple hurdles for AAV-based gene therapy to achieve its full potential. (1) Low transduction efficiency, (2) pre-existing nAb against AAVs, (3) transgene toxicity and loss of expression, and (4) extremely high price tag ([@B46]; [@B111]). Fortunately, multiple strategies have been developed to address these hurdles ([@B241]). For instance, through vector engineering, a new generation of AAV vectors can evade pre-existing nAbs while retaining a good transduction profile in the respiratory system ([@B137]; [@B240]). For rare genetic diseases, life-long gene expression is important for therapeutic purposes but could cause toxicity. On the contrary, for emerging CoVs, the goal is a short-term protection from the virus. Therefore, AAV can target epithelial cells that have a regular turn-over rate, hence providing short-term protection and preventing transgene toxicity. AAV-based therapies are known for their extremely high prices, sometime up to a million US dollar per treatment. However, the prices are inflated due to the small market size of rare genetic diseases and the cost for drug development. Given the huge market size of infectious diseases, the price for AAV-based therapy for infectious diseases should be more reasonable. Unlike rare genetic diseases and other infectious diseases, an emerging CoV outbreak is uniquely suitable for AAV-based passive immunization as a short-term protection therapy before vaccine deployment.

Conclusion {#S7}
==========

The continuous development of vaccines, antivirals, and hopefully gene therapies will provide an arsenal for combating and controlling emerging CoV diseases. For vaccine development, understanding the antigenicity and neutralizing antibody footprints of different CoVs could aid the development of broad-spectrum vaccines and, ultimately, the possibility of a universal CoV vaccine. Vaccine formulation, including dosage and adjuvants, should be tested systemically and, if possible, on animal models that reflects the genetic variation of the human population. A deeper understanding of the basic biology of CoV and host-virus interaction can lead to the discovery of druggable targets. Importantly, we should not overlook the potential of the existing broad-spectrum antivirals and should start clinical trials on these drugs in a timely fashion. Prevention is always the best treatment, and constant viral surveillance of wild animals for potential emerging CoVs is extremely important. Testing the outbreak potential of heterologous SARS- and MERS-like viruses with different spike proteins could better prepare society from the next outbreak. A centralized digital database that collect public health and clinical information of the current outbreak would allow global retrospective studies in the future using machine learning and other big data analysis. On the research side, quick, reliable and easily employed viral testing kits should be developed. Innovative technologies such as gene therapy should be adequately explored for their potential to combat CoVs and act as another line of defense against elusive emerging viral diseases. The current SARS-CoV-2 poses a huge challenge for society; however, given experience with emerging CoVs and global effort, it is hoped that the impact of the outbreak will be minimal.
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